Gene fusions represent an important class of somatic alterations in cancer. They have become important biomarkers for cancer diagnosis, prognosis, and targeted therapies due to their inherent expression in tumor tissue alone. Biocartis is developing diagnostic tools for these fusions. The aim of this study is to evaluate the diagnostic accuracy of the Idylla™ GeneFusion Panel 1.x against the comparators chosen as per the intended purpose. Biobank samples will be used to evaluate the accuracy of the company’s GeneFusion Panel.